1. Home
  2. BEAM vs NTCT Comparison

BEAM vs NTCT Comparison

Compare BEAM & NTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.48

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

HOLD

Current Price

$38.44

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
NTCT
Founded
2017
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.9B
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
BEAM
NTCT
Price
$27.48
$38.44
Analyst Decision
Buy
Buy
Analyst Count
12
2
Target Price
$50.75
$31.00
AVG Volume (30 Days)
2.1M
503.1K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
125.39
EPS
N/A
0.29
Revenue
$24,000.00
$891,820,000.00
Revenue This Year
N/A
$6.02
Revenue Next Year
$33.77
$2.55
P/E Ratio
N/A
$30.87
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$21.32
52 Week High
$38.26
$45.28

Technical Indicators

Market Signals
Indicator
BEAM
NTCT
Relative Strength Index (RSI) 44.83 46.04
Support Level $26.23 $38.69
Resistance Level $29.21 $40.92
Average True Range (ATR) 1.46 1.37
MACD 0.18 -0.01
Stochastic Oscillator 67.89 58.36

Price Performance

Historical Comparison
BEAM
NTCT

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About NTCT NetScout Systems Inc.

NetScout Systems Inc is engaged in providing enterprise network observability, carrier service assurance, cybersecurity, and Distributed Denial-of-Service (DDoS), protection solutions. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

Share on Social Networks: